Home Mipsagargin Demonstrates Clinical Benefit In Subset Of Glioblastoma Patients
 

Keywords :   


Mipsagargin Demonstrates Clinical Benefit In Subset Of Glioblastoma Patients

2015-12-02 02:02:20| drugdiscoveryonline Home Page

GenSpera Inc., a biotech company developing a novel prodrug therapeutic for the treatment of cancer, recently announced results from the Phase II study investigating the use of mipsagargin (G-202) for the treatment of glioblastoma multiforme

Tags: benefit patients clinical demonstrates

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
29.03Researchers Look at Cinnamic Acid for Hair Growth
29.03Chinese smartphone giant takes on Tesla
29.03Questions raised over Temu cash 'giveaway' offer
29.03Charge of 90 to clear problem debt axed for poorest
29.03India's army of gold refiners face new competition
28.03Amorepacific Patents Hair Growth Compositions with Camellia Kaempferol Glycoside
28.03Dry Shampoo That Provides Color Patented by Church & Dwight
28.03FTX's Sam Bankman-Fried sentenced to 25 years
More »